SEVERE IMMUNE HEMOLYTIC ANEMIA AFTER LIVER TRANSPLANTATION
https://doi.org/10.15825/1995-1191-2013-2-109-112
Abstract
Clinical case of successful treatment of severe immune hemolytic anemia after liver transplantation is represen- ted in this article. The cause of complication was so-called passenger lymphocyte syndrome (a type of graft- versus-host disease). Two plasmapheresis sessions and Ig (0.5 g/kg) in combination with increased maintenance immunosuppression with a short course of oral methylprednisolone in a total dose of 150 mg during 12 days were effective. The patient was discharged from hospital 34 days after transplantation in a satisfactory condition with a stable hemoglobin level.
About the Authors
A. I. Sushkov
Liver and Kidney transplantation division (Head – prof. Y.G. Moysyuk) Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation (Head – academician of RAMSci, prof. S.V. Gautier) Moscow, Russian Federation
Y. O. Malinovskaya
Liver and Kidney transplantation division (Head – prof. Y.G. Moysyuk) Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation (Head – academician of RAMSci, prof. S.V. Gautier) Moscow, Russian Federation
I. A. Miloserdov
Liver and Kidney transplantation division (Head – prof. Y.G. Moysyuk) Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation (Head – academician of RAMSci, prof. S.V. Gautier) Moscow, Russian Federation
Y. G. Moysyuk
Liver and Kidney transplantation division (Head – prof. Y.G. Moysyuk) Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation (Head – academician of RAMSci, prof. S.V. Gautier) Moscow, Russian Federation
Department of Transplantology and Artificial organs (Head – academician of RAMSci,
prof. S.V. Gautier) I.M. Sechenov First Moscow State Medical University (Rector – corresponding member of RAMSci, prof. P.V. Glybochko), Moscow, Russian Federation
References
1. Maruyama S. Red blood cell status in alcoholic and non-alcoholic liver disease // J. Lab. Clin. Med. 2001; 138 (5): 332–337.
2. Misra S. Profile of anemia in children after liver trans- plantation // Transplantation. 2000; 70 (10): 1459–1463.
3. Randomised trial comparing tacrolimus (FK506) and cy- closporin in prevention of liver allograft rejection // Eu- ropean FK506 Multicentre Liver Study Group. Lancet.
4. ; 344 (8920): 423–428.
5. Wiesner R. A randomized double-blind comparative study
6. of mycophenolate mofetil and azathioprine in combinati- on with cyclosporine and corticosteroids in primary liver transplant recipients // Liver Transpl. 2001; 7 (5): 442–450.
7. Maheshwari A., Mishra R., Thuluvath P.J. Post-liver- transplant anemia: etiology and management // Liver Transpl. 2004; 10 (2): 165–173.
8. Yazer M.H., Triulzi D.J. Immune hemolysis following AB0-mismatched stem cell or solid organ transplantati- on // Curr. Opin. Hematol. 2007; 14 (6): 664–670.
9. Shortt J. A ‘dangerous’ group 0 donor: severe hemolysis in all recipients of organs from a donor with multiple red cell alloantibodies // Am. J. Transplant. 2008; 8 (3): 711–714.
10. Seltsam A. Donor-derived alloantibodies and passenger lymphocyte syndrome in two of four patients who recei- ved different organs from the same donor // Transfusion. 2001; 41 (3): 365–370.
11. Salerno C.T. Donor-derived antibodies and hemolysis after ABO-compatible but nonidentical heart-lung and lung transplantation // Transplantation. 1998; 65 (2): 261–264.
12. Panaro F. Severe hemolytic anemia due to passenger lymphocytes after living-related bowel transplant // Clin. Transplant. 2004; 18 (3): 332–335.
13. Sokol R.J. Posttransplant immune-mediated hemolysis // Transfusion. 2002; 42 (2): 198–204.
14. Berenguer M. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppressi- on // J. Hepatol. 2006; 44 (4): 717–722.
15. Humar A. Steroid minimization in liver transplant re- cipients: impact on hepatitis C recurrence and post- transplant diabetes // Clin. Transplant. 2007; 21 (4): 526–531.
16. Lefaucheur C. Comparison of combination Plasmaphe- resis/IVIg/anti-CD20 versus high-dose IVIg in the treat- ment of antibody-mediated rejection // Am. J. Transplant. 2009; 9 (5): 1099–1107.
17. Bartel G., Schwaiger E., Bohmig G.A. Prevention and treatment of alloantibody-mediated kidney transplant re- jection // Transpl. Int. 2011; 24 (12): 1142–1155.
18. Marfo K. Desensitization protocols and their outcome // Clin. J. Am. Soc. Nephrol. 2011; 6 (4): 922–936.
19. Jordan S.C. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation // Trans. Am. Clin. Climatol. Assoc. 2006; 117: 199–211; discussion 211.
20. Lee H.J. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Trans- plant. 2008; 42 (1): 67–69.
21. Hoffman P.C. Immune hemolytic anemia-selected to- pics // Hematology Am. Soc. Hematol. Educ. Program. 2006: 13–18.
Review
For citations:
Sushkov A.I., Malinovskaya Y.O., Miloserdov I.A., Moysyuk Y.G. SEVERE IMMUNE HEMOLYTIC ANEMIA AFTER LIVER TRANSPLANTATION. Russian Journal of Transplantology and Artificial Organs. 2013;15(2):109-112. (In Russ.) https://doi.org/10.15825/1995-1191-2013-2-109-112
Views:
2260
Email this article 